Kolon Life Science Registers Indonesian Patent for "Cartilage Regeneration"

Kolon Life Science announced on August 26 that its affiliate, Kolon TissueGene, has received a patent registration decision in Indonesia for "cartilage regeneration using chondrocytes and TGF-β" related to its osteoarthritis cell and gene therapy, TG-C (formerly Invossa), which is currently under development.

Kolon Life Science Headquarters. Kolon Life Science

With this patent registration decision, Kolon Life Science has further strengthened its technological and commercial position in Indonesia by securing not only the existing TG-C implementation rights from Kolon TissueGene but also legal protection based on patent rights.

The patent covers a technical method for producing transfected cells by introducing the "TGF-β1" gene (which promotes anti-inflammatory effects and cartilage component production) into human embryonic kidney-derived GP2-293 cells. This enables the induction of tissue and hyaline cartilage regeneration, which is expected to restore joint function and improve structural integrity.

In particular, the transfected GP2-293 cells have undergone irradiation to completely eliminate tumorigenicity, and they are designed to die off after expressing the TGF-β1 protein for a certain period. Additionally, by applying a direct intra-articular injection method, systemic exposure is prevented, significantly enhancing safety.

This patent has been registered in five countries, including Indonesia, China, Japan, Australia, and the Philippines. Kolon Life Science holds exclusive rights to produce and sell TG-C in these regions and has the authority to restrict unauthorized use of its technology by third parties. With this patent registration decision, Kolon Life Science has further reinforced its position in Indonesia by securing both exclusive implementation rights and legal protection based on patent rights.

According to global market research firm Grand View Research, the osteoarthritis therapeutics market in the Asia-Pacific region is expected to grow at an average annual rate of 9.3% from 2025 to 2030, reaching approximately 3.36 billion USD (about 4.66 trillion KRW) by 2030. Indonesia, in particular, is considered one of the most promising bio and medical markets in Southeast Asia, with active adoption of advanced medical technologies and the establishment of clinical infrastructure. As such, TG-C’s entry into the Indonesian market is expected to serve as a bridgehead for further expansion into the broader Asian market.

Kim Sunjin, CEO of Kolon Life Science and Chief Medical Officer of Kolon TissueGene, stated, "This patent registration decision in Indonesia is further international recognition of TG-C’s technological capabilities and safety. Based on this, we will accelerate our entry into the global market, including Indonesia."

This content was produced with the assistance of AI translation services.